trial

To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

NCTId NCT00141479
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment —
Sponsored by Solvay Pharmaceuticals
Primary completion 2006-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
—
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2005-05
Primary completion
2006-11
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Bifeprunox

Sponsors

Solvay PharmaceuticalsLead Sponsor
H. Lundbeck A/SCollaborator
Wyeth is now a wholly owned subsidiary of PfizerCollaborator

Investigators

1
Global Clinical Director SolvayStudy Director

Sites

1 total
Wichita, United States

Linked catalysts

1
To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox — primary completion2006-11

Facts & assertions

3 sourced
Phase
PHASE2
Primary Completion Date
2006-11
Status
COMPLETED
relationships
The graph out of here
drug
Bifeprunox
drug
lead_sponsor
Solvay Pharmaceuticals
company
collaborator
H. Lundbeck A/S
company
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Global Clinical Director Solvay
person